Skip to main content
SpringerLink
Log in

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although there is insufficient evidence for the treatment of older patients with advanced gastric cancer, fluorouracil combined with platinum chemotherapy has been recognized as a standard first-line treatment for such populations in Japan despite the lack of efficacy and toxicity data.

Methods

Patients aged 75 years or older with advanced gastric cancer were enrolled. S-1 plus docetaxel (docetaxel: 40 mg/m2, day 1; S-1: 80 mg/m2, days 1–14; q21 days) was repeated every 3 weeks. The primary endpoint was overall response rate. Secondary endpoints were safety, progression-free survival, time to treatment failure, and overall survival. The sample size was calculated as 30 under the hypothesis of an expected response rate of 40% and a threshold response rate of 20%, at a power of 90% and a two-sided alpha value of 5%.

Results

From February 2010 to January 2015, 31 patients were enrolled and assessed for efficacy and toxicity. The response rate was 45.2% (95% CI 27.3%–64.0%; p = 0.001) and it exceeded the expected response rate set at 40%. Median progression-free survival was 5.8 months, the 1-year survival rate was 58.1%, and the median survival time was 16.1 months. The major grade 3/4 adverse events were neutropenia (58%), febrile neutropenia (13%), anemia (10%), anorexia (10%), and fatigue (6%).

Conclusions

These findings indicate that S-1 plus docetaxel as first-line treatment for older patients is feasible and that it has promising efficacy against advanced gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) Available at: https:// ganjoho.jp /reg_stat /statistics /stat/ summary.html [Last accessed on January 7th, 2023]

  2. Efrat D, Louise CW, Ilene SB et al (2021) NCCN guidelines insights: older adult oncology, version 1.2021. J Natl Compr Canc Netw. 19(9):1006–1019

    Article  Google Scholar 

  3. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358(1):36–46

    Article  CAS  PubMed  Google Scholar 

  4. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997

    Article  PubMed  Google Scholar 

  5. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221

    Article  CAS  PubMed  Google Scholar 

  6. Japanese Gastric Cancer Association (2021) Japanese gastric cancer treatment guidelines (Ver. 6). Kanehara, Tokyo

    Google Scholar 

  7. Makiyama A, Kunieda K, Noguchi M et al (2018) First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer 21:792–801

    Article  CAS  PubMed  Google Scholar 

  8. Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141–148

    Article  CAS  PubMed  Google Scholar 

  9. Yamaguchi K, Shimamura T, Hyodo I et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803–1808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yoshida K, Ninomiya M, Takakura N et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402–3407

    Article  CAS  PubMed  Google Scholar 

  11. Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24(22):3657–3663

    Article  CAS  PubMed  Google Scholar 

  12. Berthold DR, Pond GR, Freidele S (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26(2):242–245

    Article  CAS  PubMed  Google Scholar 

  13. 30th Annual San Antonio Breast Cancer Symposium (2007) Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735. Breast Cancer Res Treat 106(Suppl 1):Abstract 12

    Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

    Article  CAS  PubMed  Google Scholar 

  15. Koizumi W, Kim YH, Fujii M et al (2014) Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 140(2):319–328

    Article  CAS  PubMed  Google Scholar 

  16. Imamura H, Kishimoto T, Takiuchi H et al (2014) Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother 26(1):57–61

    Article  CAS  PubMed  Google Scholar 

  17. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    Article  CAS  PubMed  Google Scholar 

  18. Chin K, Takahari D, Kawabata R et al (2022) Initial safety analysis of CapeOx for elderly patients with advanced gastric cancer patients: a phase II trial. Anticancer Res 42:2683–2687

    Article  CAS  PubMed  Google Scholar 

  19. Hall PS, Swinson D, Cairns DA et al (2021) Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer the go2 phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.0848

    Article  PubMed  PubMed Central  Google Scholar 

  20. Jiang Z, Zhou A, Sun Y et al (2022) Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the frst-line therapy: a single-arm, phase 2 study. BMC Cancer 22:253. https://doi.org/10.1186/s12885-022-09332-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jatoi A, Murphy BR, Foster NR et al (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29–34

    Article  CAS  PubMed  Google Scholar 

  22. Luo HY, Xu RH, Wang F et al (2010) Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 56:94–100

    Article  CAS  PubMed  Google Scholar 

  23. Kuo YC, Liu HT, Lin YL et al (2014) Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center. Biomed J 37:141–146

    PubMed  Google Scholar 

  24. Chao Y, Hsieh JS, Yeh HT et al (2014) A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol 73:799–806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all the patients and their families. We also thank Hiroshi Furukawa and Toshimasa Tsujinaka for advice on the study conception and design; Toshimasa Tsujinaka for statistical analyses of data; and Akemi Morita for data management. Additionally, we thank H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Department of Surgery, Toyonaka Municipal Hospital, 4-14-1 Shibahara-cho, Toyonaka-city, Japan

    Tomono Kawase & Hiroshi Imamura

  2. Department of Surgery, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai-city, Japan

    Ryohei Kawabata & Kazuhiro Nishikawa

  3. Department of Surgery, Osaka Rosai Hospital, 1179-3 Nakasone-cho, Kita-ku, Sakai-city, Japan

    Ryohei Kawabata

  4. Department of Gastroenterological Surgery, Higashiosaka City Medical Center, 3-4-5 Nishiiwata, Higashiosaka-city, Japan

    Jin Matsuyama

  5. Department of Medical Oncology, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka-city, Japan

    Kazuhiro Yanagihara

  6. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita-city, Japan

    Kazuyoshi Yamamoto & Yukinori Kurokawa

  7. Department of Gastroenterology, Bellland General Hospital, 500-3 Higashiyama, Naka-ku, Sakai-city, Japan

    Noriyuki Hoki

  8. Department of Surgery, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao-city, Japan

    Junji Kawada

  9. Department of Medical Oncology, Faculty of Medicine, Kindai University, 377-2 Oonohigashi, Sayama-city, Japan

    Hisato Kawakami

  10. Department of Medical Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Japan

    Daisuke Sakai

  11. Clinical Study Support Center, Wakayama Medical University, 811-1 Kimiidera, Wakayama-city, Japan

    Toshio Shimokawa

  12. Palliative and Supportive Care Center, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita-city, Japan

    Taroh Satoh

Authors
  1. Tomono Kawase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryohei Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin Matsuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiro Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Yanagihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuyoshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Noriyuki Hoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junji Kawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hisato Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Daisuke Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yukinori Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Toshio Shimokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Taroh Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Hiroshi Imamura designed and supervised the research. Material preparation, data collection and analysis were performed by TS. The first draft of the manuscript was written by TK, HK: reviewed and modified the manuscript and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hiroshi Imamura.

Ethics declarations

Conflict of interest

Hiroshi Imamura has received honoraria from Taiho Pharmaceutical Co., Ltd. Kazuhiro Nishikawa has received honoraria from Bristol-Myers Squibb Co., Ltd., Daiichi Sankyo, Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hisato Kawakami has has received honoraria from BMS K.K., ONO Pharmaceutical Co., LTD., Eli Lilly Japan K.K., MSD K.K., and Daiichi Sankyo, Co., Ltd., fees for promotional materials from ONO Pharmaceutical Co., LTD., üMSD K.K., and Daiichi Sankyo, Co., Ltd., and research funding from BMS K.K., Eisai Co., Ltd., and Kobayashi Pharmaceutical Co. Ltd. Daisuke Sakai has received honoraria from Daiichi Sankyo Co. Ltd., and Chugai Pharmaceutical Co., Ltd., and research funding from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Yukinori Kurokawa has received lecture fees and research grant from Taiho Pharmaceutical Co., Ltd. Taroh Satoh has received honoraria from ONO Pharmaceutical Co., Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Taiho Pharmaceutical Co., Ltd., research funding from ONO Pharmaceutical Co., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., and Hutch Med Co., Ltd., scholarship donations from Taiho Pharmaceutical Co., Ltd., and endowed chairs from ONO Pharmaceutical Co., Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co. All the remaining authors have no conflicts of interest to declare.

Ethical approval

All procedures in this study were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants before entry into the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawase, T., Imamura, H., Kawabata, R. et al. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902). Int J Clin Oncol 29, 134–141 (2024). https://doi.org/10.1007/s10147-023-02437-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-023-02437-4

Keywords

Search

Navigation